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Strain differenceRoles of complement factors in prion infection of the central nervous system remain unclear. In this study, we
assessed the strain-dependent reactivity of complement factors in prion infections of Neuro2a (N2a) cells
and mouse brains. N2a cells persistently infected with either Chandler or 22L scrapie strains were cultured
in the presence of normal mouse serum (NMS), followed by staining with phosphatidylserine binding protein
and early apoptosis marker Annexin V. The proportion of Annexin V positive cells was increased both in
Chandler- and 22L-infected cells. Preincubation of NMS with anti-C1q, C3 and/or C9 antibodies reduced
Annexin V positive cells in Chandler-infected cells, while only anti-C3 antibodies were effective on 22L-
infected cells. The immunohistochemistry showed that deposition of C1q and C3 was different between
Chandler- and 22L-infected mouse brains. These results indicate that the reactivity of complement factors dif-
fers between prion strains both in vitro and in vivo.
© 2011 Elsevier Inc. All rights reserved.Introduction
The complement system plays key roles in the immune system in-
cluding regulation of immune reactions and the elimination of phago-
cytosed antigens, immune complexes, tumor cells and apoptotic cells.
Complement factors also have multiple functions for synapse remo-
deling (Stevens et al., 2007), neurogenesis (Shinjyo et al., 2009), cell
survival (Dashiell et al., 2000; Soane et al., 1999, 2001) and cell
death (Ren et al., 2008). Complement factors also seem to be involved
in pathogenesis of neurodegenerative disease such as Alzheimer's
disease (AD). Previous studies showed that β-amyloid, the major con-
stituent of senile plaques, binds C1q and induces complement activa-
tion, which may promote either neuroprotection or neurotoxicity
(Guan et al., 1994; Sarvari et al., 2003; Webster et al., 1997).
Prion diseases are fatal neurodegenerative disorders including
scrapie in sheep and goats, bovine spongiform encephalopathy in cat-
tle, chronic wasting disease in cervids and Creutzfeldt–Jakob disease
in humans. These diseases are characterized in the central nervous
system (CNS) by deposition of abnormal forms of prion protein (e.g.
PrPSc), vacuolation of neural tissue, astrocytosis and microglial activa-
tion. Previous studies using C1q, factor B/C2 or C3 depleted mice
(Klein et al., 2001; Mabbott et al., 2001) have implicated the involve-
ment of these complement factors in the spread of prions from pe-
ripheral tissues to CNS. Klein et al. (2001) and Zabel et al. (2007)Hygiene, Graduate School of
ita 18, Kita-ku, Sapporo 060-
Hasebe).
rights reserved.showed that complement receptor CD21/35 on follicular dendritic
cells has an important role in lymphoid prion accumulation and neu-
roinvasion of prion. Flores-Langarica et al. (2009) demonstrated that
C1q is involved in PrPSc uptake into conventional dendritic cells,
which have an important role in the prion propagation from the pe-
ripheral tissue to the CNS. Direct binding of C1q to amyloid ﬁbrils,
beta-oligomers prepared from human or mouse recombinant PrP
and puriﬁed PrPSc, resulting in activation of the classical complement
pathway, has been demonstrated in vitro, suggesting that prion infec-
tion induces complement activation (Blanquet-Grossard et al., 2005;
Dumestre-Perard et al., 2007; Erlich et al., 2010; Mitchell et al.,
2007; Sim et al., 2007; Sjoberg et al., 2008).
Klein et al. (2001) and Mabbott et al. (2001) suggested that com-
plement factors seem to be less important in the CNS than the periph-
ery, because depletion of either C1q, factor B/C2 or C3 did not affect
the survival period of mice intracerebrally infected with Chandler
and ME7 scrapie. Mabbott and Bruce (2004) showed that the incuba-
tion periods of C5 deﬁcient mice infected with ME7 and 79A scrapie
via intracerebral or peripheral route were similar to those of wild
type mice. However, there still remains the possibility that comple-
ment factors are involved in neuropathogenesis of prion diseases. As-
sociation of complement factors with amyloid plaques of human
prion disease was demonstrated by immunohistochemistry (Ishii et
al., 1984; Kovacs et al., 2004). mRNA levels of C1q and C3 increase
in the brains of mice intracerebrally infected with Chandler, 22L or
ME7 strains in the pre-clinical phase of the disease, indicating that ex-
pression of complement factors is altered in the early stage of the
neuropathogenesis in some prion strains (Dandoy-Dron et al., 1998;
Hwang et al., 2009; Skinner et al., 2006).
206 R. Hasebe et al. / Virology 423 (2012) 205–213In this study, we have further assessed the possible involvement of
complement factors in the neuropathogenesis of prion disease using
murine neuroblastoma (N2a) cells and mice infected with Chandler
and 22L scrapie strains. Our data suggest that complement factors in-
duce translocation of phosphatidylserine in the plasma membrane of
prion-infected N2a cells and that the reaction of complement compo-
nents varies with prion strain.
Results
Normal mouse serum treatment induces degenerative change in scrapie-
infected N2a cells
To assess the possibility that complement factors react on scrapie-
infected cells, we used N2a cells persistently infected with Chandler
or 22L strains. For uninfected negative controls, we cured the scrapie
infection in these cell lines using pentosan polysulfate (PPS). The cells
were treated with normal mouse serum (NMS), heat-inactivated
NMS (H-NMS) or fetal bovine serum (FBS) for 6, 12, 24 and 48 h
(Fig. 1). NMS contains almost all murine complement components,
whereas these factors are inactivated in H-NMS and absent in FBS.
After these treatments, the cells were stained with Annexin V, a pro-
tein that labels phosphatidylserine in the outer leaﬂet of the plasma
membrane as a marker of an early stage of apoptosis (Koopman et
al., 1994). Time dependent increases in Annexin V-positive cells
were observed only in the cultures treated with NMS, culminating
in much higher percentages of positive cells in the Chandler- and
22L-infected N2a cultures (60–64%) than in the PPS-cured cultures
(14–18%). These results indicated that NMS treatment induced de-
generative change in Chandler- and 22L-infected N2a cells to an ex-
tent that was enhanced ~4-fold by scrapie infection. Less than 10%
of the cells treated with H-NMS and FBS were Annexin V positive, in-
dicating that the NMS factors mediating the increase in Annexin V
positivity were heat sensitive, as is known to be true for complement
factors. Moreover, a similarly low percentage of FBS-treated cells was
Annexin V-positive, indicating that bovine serum factors cannot be
substituted for murine factors in mediating the observed degenera-
tive changes. To assess if cell death occurs in these cells or not, the
cells were incubated with propidium iodide (PI) at 24 h after NMS
treatment (Fig. 1D). Although PI uptake was slightly increased in
the Chandler- and 22L-infected N2a cells compared to PPS-cured
cells, less than 10% of the cells were positive for PI, suggesting that
translocation of phosphatidylserine hardly resulted in cell death.
Different complement factors are involved in NMS-induced degenerative
changes in Chandler- and 22L-infected N2a cells
To further examine the role of murine complement factors in the
NMS-induced degenerative changes in Chandler- and 22L-infected
N2a cells, the NMS was pre-treated with anti-C1q, C3, C9 antibodies
or mixture of these antibodies. Because all of the antibodies were de-
rived from goats, we used normal goat serum (NGS) and anti-mouse
IgG goat serum as controls. In Chandler-infected N2a (Fig. 2A), the
pretreatment with individual anti-C1q, C3 or C9 antibodies reduced
the proportion of Annexin V positive cells (pb0.01 vs pretreatment
with NGS or anti-mouse IgG, Student's t test). The mixtures of anti-
C1q+C3 and anti-C1q+C3+C9 were even more effective than the
individual anti-C1q, C3 or C9 antibodies (pb0.01, Student's t test),
suggesting that multiple complement components are involved in
the degeneration of Chandler-infected N2a cells. In contrast, in 22L-
infected cells (Fig. 2B), the anti-C1q and anti-C9 antibodies were inef-
fective, while the anti-C3 antibody alone reduced the percentage of
Annexin V positive cells as effectively as combinations of antibodies to
C1q+C3, C3+C9 and C1q+C3+C9. These results suggested that
only C3 was involved in the degenerative change of 22L-infected N2a
cells. The involvement of multiple complement factors in the inductionof Annexin V positivity in Chandler-infected N2a cultures (Fig. 2A)
raised the possibility that membrane attack complex (MAC) formation
occurs on the plasmamembrane on these cells. To assess this possibility,
we performed immunocytochemistry for MAC on Chandler-, 22L-
infected (Fig. 2C) or PPS-cured N2a cells (data not shown). In
Chandler-infected N2a cells, MAC was detected at 24 h after treatment,
suggesting that MAC formation occurred on Chandler-infected N2a
cells, but not on 22L-infected and PPS-cured N2a cells.C1q colocalizes with PrP in Chandler-infected N2a cells
To examine if C1q is associated with PrP in scrapie-infected or
PPS-cured N2a cells after exposure to NMS, we performed double
staining of C1q (green) and PrP (red) under non-denaturing condi-
tion (Fig. 3). In Chandler-infected N2a cells, colocalization of C1q
with PrP (yellow) was detected at 30 min and 1 h. In 22L-infected
cells, colocalization was not detected at any time point and C1q stain-
ing seemed localized in the cytoplasm more than on the cell surface.
C1q staining was hardly detected in PPS-cured cells at any time
point. No C1q staining was detected in untreated cells (data not
shown). These results suggest that PrP on Chandler-infected N2a
cells was associated with C1q on the cell surface.C3 colocalizes with PrP in 22L-infected N2a cells
Next we analyzed the association of C3 with PrP in scrapie-
infected or PPS-cured N2a cells (Fig. 4). In 22L-infected cells, coloca-
lization of C3 and PrP was detected in the cytoplasm and on the cell
surface at 15 and 30 min after NMS treatment. Although C3 staining
was observed rarely in Chandler-infected or PPS-cured N2a cells, no
colocalization was detected. No staining was detected in untreated
cells (data not shown). These results suggest that PrP on 22L-
infected N2a cells was associated with C3 on the cell surface and in
the cytoplasm.Distribution of C1q and C3 in scrapie-infected mouse brain
We also analyzed the distributions of vacuolar lesions, PrPSc, C1q
and C3 in Chandler-, 22L- or mock-infected mouse brains (Figs. 5 &
6). At 90 dpi (pre-clinical stage of the disease) in Chandler-infected
mouse brains, mild vacuolar degeneration was observed in the thala-
mus. PrPSc was strongly detected in the thalamus, moderately in sec-
ondary motor cortex and mildly in retrosplenial agranular cortex,
septum, CA1 of hippocampus, midbrain, pons and medulla of the cer-
ebellum. The C1q distribution was almost consistent with PrPSc ex-
cept in the secondary motor cortex. Mild deposition of C3 was
detected in cerebral cortex, septum, stria medullaris of thalamus,
midbrain and pons. Vacuolar lesions in the major part of thalamus
lacked deposition of C3 (Fig. 6). In 22L-infected mouse brains at
90 dpi, mild vacuolar lesions and PrPSc were distributed similar to
those in Chandler-infected mice. However, in contrast to the
Chandler-infected mice, the dorsal part of thalamus lacked C1q im-
munoreactivity, despite the presence of vacuolar lesions and PrPSc
(Fig. 6). Moreover, C3 staining was much more pronounced in the
thalamus (Fig. 6) and also was distributed widely throughout other
regions including the hypothalamus, stria terminalis, septum, cerebral
cortex, midbain, pons, medulla oblongata and medulla of the cerebel-
lum(Fig. 5). These results suggested that therewere differences in com-
plement activation between Chandler- and 22L-infected mouse brains
at 90 dpi. At 133 and 166 dpi, C1q and C3 signals were widely distribut-
ed both in Chandler- and 22L-infected infected mouse brains and there
was no substantial difference between the two scrapie strains (data not
shown). Neither C1q nor C3 signal was detected in mock-infected
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Fig. 1. Effects of treatment of scrapie-infected N2a cells with NMS. (A) Annexin V staining on N2a cells treated with NMS. Chandler-infected, 22L-infected or PPS-cured (from
Chandler or 22L infection, respectively) N2a cells were seeded in 24 well plates and cultured for 2 days. The cells were treated with 10% NMS for 24 h and stained with Annexin
V. Bars show 20 μm. (B) Time course of the percentage of Annexin V positive cells in Chandler-infected and PPS-cured N2a cells. The cells were treated with NMS, H-NMS or
FBS for 6, 12, 24 and 48 h and stained with Annexin V. The graphs show the means of the proportion of Annexin V positive cells in three ﬁelds. The error bars show standard
deviation (SD). Gray bars, NMS treated cells. White bars, HS treated cells. Black bars, FBS treated cells. *pb0.01 vs H-NMS or FBS-treated cells (Student's t test). The results are
representative of 3 independent experiments. (C) Time course of the percentage of Annexin V positive cells in 22L-infected and PPS-cured N2a cells. The graphs show the mean
of the proportion of Annexin V positive cells in three ﬁelds. The error bars show SD. Gray bars, NMS treated cells. White bars, H-NMS treated cells. Black bars, FBS treated cells.
*pb0.01 vs HS or FBS-treated cells (Student's t test). The results are representative of 3 independent experiments. (D) PI uptake into N2a cells treated with NMS. Chandler-infected,
22L-infected or PPS-cured (from Chandler or 22L infection, respectively) N2a cells were seeded in 24 well plates and cultured for 2 days. The cells were treated with 10% NMS for
24 h and stained with PI. Bars show 50 μm.
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Our current data suggest that the reaction of complement factors
differs between Chandler and 22L scrapie strains. There are multiple
distinct prion strains distinguished by biological and biochemical typ-
ing, even though the amino acid sequence of the constituent protein
is identical. Strains can differ in incubation period, neuropathology,
cellular tropism, the size of protease-resistant PrPSc fragments, PrPSc
glycosylation ratios, and PrPSc conformation (Bessen and Marsh,
1992; 1994; Bruce et al., 1989; Caughey et al., 1998; Kuczius andGroschup, 1999; Mahal et al., 2007; Safar et al., 1998). In this study,
we used two mouse-adapted scrapie strains, Chandler and 22L.
These two strains can be distinguished by biochemical typing, such
as PrPSc glycoform proﬁles, replication efﬁciency in cell culture, and
conformation (Atarashi et al., 2006; Baron et al., 2011; Mahal et al.,
2007; Nishida et al., 2000; Sim and Caughey, 2009). In contrast, bio-
logical properties of these strains, such as incubation period, distribu-
tion of pathological lesions and deposition of PrPSc, are similar,
although the vacuolar lesions in the cerebellum are more prominent

























































Fig. 2. Effects of pre-incubation of NMS with anti-complement antibodies on the number of Annexin V positive cells in Chandler- (A) and 22L-infected N2a cells (B). NMS were
incubated with anti-C1q, C3 and/or C9 goat serum for 3 h at 4 °C. Then Chandler- or 22L-infected cells were treated with the NMS. For the control, NMS were treated with normal
goat serum (NGS) or anti-mouse IgG goat serum (IgG). The graphs show the means of the proportions of Annexin V positive cells in three ﬁelds. The error bars show SD. *pb0.01 vs
NGS or IgG-treated NMS (Student's t test). The results are representative of 3 independent experiments. (C) MAC formation on Chandler- and 22L-infected N2a cells after NMS
treatment. The cells were treated with NMS for 6, 12 and 24 h, ﬁxed and subjected to immunocytochemistry for MAC. Red, MAC. Blue, DAPI. Bars show 10 μm.
208 R. Hasebe et al. / Virology 423 (2012) 205–213evidence that differential reactivity with complement factors is a bio-
logical feature that discriminates the Chandler and 22L strains. Ac-
cordingly, it will also be of interest to compare the involvement of
complement factors in infections with other mouse-adapted scrapie
strains, such as Obihiro, G1 and ME7 that have distinct biological
properties (i.e., incubation period, distribution of pathological lesions,
glial activation).
The reason for the difference in complement factor reactivity be-
tween the Chandler and 22L strains remains unclear. Our confocal mi-
croscopy data indicate that PrP was colocalized with C1q in Chandler-
infected N2a cells, whereas PrP in 22L-infected N2a cells was colocalized
with C3. The resolution of confocal microscopy does not allow us to con-
clude unequivocally that complement factors bind directly to PrP or
PrPSc. However, one of the possible explanations for different comple-
ment reactivities of Chandler and 22L PrPSc is that they directly bind to
C1q and C3 with different relative afﬁnities. Another possibility is that
these strains have different afﬁnities for inhibitors of C5 convertase andMAC formation, such as C4b binding protein, clusterin, CD59 and ﬁbro-
nectin (Speth et al., 2008), resulting in differences in MAC formation on
Chandler and 22L-infected N2a cells. Recombinant PrP, ﬁbrils, oligomers
and puriﬁed PrPSc directly bind C1q in vitro and induce complement ac-
tivation (Blanquet-Grossard et al., 2005; Dumestre-Perard et al., 2007;
Mitchell et al., 2007; Sim et al., 2007; Sjoberg et al., 2008). Moreover
Veerhuis et al. (2005) reported that C1q enhanced PrP-peptide ﬁbril for-
mation. C4b binding protein also binds recombinant PrP in vitro (Sjoberg
et al., 2008). However, further study is needed to demonstrate whether
pathogenic forms of PrP bind complement factors and/or their inhibitors
in prion infections in vivo and in cultured cells.
We didn't detect colocalization of C3 and PrP in Chandler-infected
N2a cells, which seems to be conﬂicting with respect to involvement
of C3 for the Chandler strain in translocation of phosphatidylserine in
N2a cells. We suggest two possibilities for the reason. One is that C3
may be involved in the process of MAC formation through classical
and/or lectin pathways without directly binding to PrP/PrPSc. Another
Fig. 3. Localization of PrP and C1q in scrapie-infected N2a cells treated with NMS. The cells were treated with NMS for 15, 30 min or 1 h at 37 °C and ﬁxed with 4% PFA 4% sucrose for
double immunostaining of PrP (red) and C1q (green). The nuclei were counterstained with DAPI (blue). Bars show 10 μm. Arrows show merged signals.
209R. Hasebe et al. / Virology 423 (2012) 205–213possibility is that C3 may bind PrP only in the absence of C1q because
of the former's lower afﬁnity to PrP/PrPSc. Extensive additional exper-
iments would be required to discriminate between these possibilities.
Annexin V has a high afﬁnity for phosphatidylserine (Koopman et
al., 1994), which is exposed from the inner layer to the outer layer of
the plasma membrane in the early stages of cell death by apoptosis
and necrosis (Fadok et al., 1992). In the current study, we found that
infected N2a cells were stained with Annexin V after NMS treatment.
However, the cells had not progressed to either full-blown apoptosis
or necrosis because less than 10% of the cells were stained with PI at
24 h after treatment. In addition, the cells were negative for cleaved
caspase-3 at 24 h (data not shown). A similar phenomenon has been
reported when human B cells are treated with C3 (Lόbner et al.,
2009); i.e., the cells were positive for Annexin V, but were negative for
cleaved caspase-3. Segmentation of nuclei was not observed. Therefore,
our data suggest that complement factors induced translocation of
phosphatidylserine, without cell death. The other factors may be re-
quired for cell death in prion infections.
The relatively strong deposition of PrPSc in the thalami of
Chandler- and 22L-infected mice at the preclinical 90 dpi time point
seems likely to account for the mild vacuolation and deposition of ei-
ther C1q or C3, respectively, in this region. Although we do not have
any evidence that these complement factors were activated, there is a
possibility that complement activation may occur relatively strongly
in the thalamus at this time point, and be involved in neuropathogen-
esis. However, the functional/clinical consequences on the thalamic le-
sions in particular are not clear because by the onset of clinical signs, theaccumulation of PrPSc, complement factors, gliosis and vacuolation is
more evenly distributed throughout the brain.
The immunohistochemistry data showed widespread distribution
of C1q both in Chandler- and 22L-infected mouse brains, although the
dorsal part of thalamus in 22L-infected mice lacked C1q immunoreac-
tivity. We suspect that signals stimulating C1q synthesis may not be
different between Chandler and 22L infection, but that activation of
C1q might be limited in 22L infections. Indeed, C1q in normal
mouse serum was not involved in inducing Annexin V positivity in
22L-infected N2a cells. With respect to the immunohistochemistry
data, we think that reactivity of complement factors may be different
in vivo as well as in N2a cells.
It is also unclear whether complement activation might work to
alleviate or worsen disease because of multifunctionality of comple-
ment factors in vivo. Nonetheless, we suggest two possibilities for
the roles of complement factors in prion infections from our current
data. One possibility is that complement factors facilitate microglial
phagocytosis of prion-infected neurons by exposing phosphatidylser-
ine on the cell surface. Although phosphatidylserine itself works as an
“eat-me” signal and promotes phagocytosis (Marguet et al., 1999), it
has been reported that binding of C1q and C3b on the cell surface
also facilitates phagocytosis. Because phosphatidylserine has been
known as a C1q binding molecule (Païdassi et al., 2008), exposure
of phosphatidylserine may result in further deposition of C1q, which
in turn may accelerate phagocytosis of the target cells. Another possi-
bility for the roles of complement factors is to cause degeneration of
prion-infected neurons. Bordin and Whitﬁeld (2003) showed that
Fig. 4. Localization of PrP and C3 in scrapie-infected N2a cells treated with NMS. The cells were treated with NMS for 15, 30 min, or 1 h and ﬁxed with 4% PFA 4% sucrose in PBS for
double immunostaining of PrP (red) and C3 (green). The nuclei were counterstained with DAPI (blue). Bars show 10 μm. Arrows show merged signals.
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reported that C1q is involved in removal of excess synapses in devel-
opment (Stevens et al., 2007). C3 is reported to induce translocation
of phosphatidylserine from the inner to the outer of the plasmamem-
brane in human B cells (Lόbner et al., 2009). MAC is composed of C5b,
C6, C7, C8 and multiple C9 (C5b-9), which form transmembrane
channels on the plasma membrane resulting in lysis by ﬂuid inﬂux
into the cells. When the number of the C5b-9 molecules on the target
membrane is limited, cell lysis does not occur. However, the C5b-9
molecules in sublytic conditions have a pro-apoptotic effect by medi-
ating cellular signaling pathways (Hughes et al., 2000). MAC formed
on the Chandler-infected N2a cells could have been sub-lytic in our
experiments because cell lysis was not observed. However, some pre-
vious studies have reported that complement factors C1q and C3 have
anti-apoptotic and neuroprotective effects as well (Benoit and
Tenner, 2011; Dashiell et al., 2000; Rus et al., 1996). Interestingly,
Erlich et al. (2010) suggested that C1q binds small oligomers derived
from murine recombinant PrP and inhibits cytotoxic effects of PrP
oligomers. It is possible that complement factors have both neurotoxic
and neuroprotective effects and that the role of the complement factors
may be different depending on the stage of the disease.
In conclusion, our data provide evidence that the reaction of comple-
ment factors varieswith the prion strains and that complement reactions
can induce the translocation of phosphatidylserine in the membrane of
prion-infected N2a cells. The roles of complement factors in prion infec-
tionmight be further elucidated in the future using ex vivo systems such
as slice cultures and mixed cultures of neurons and glial cells.Materials and methods
Antibodies
Anti-complement C1q, C3 and C9 goat polyclonal antibodies were
purchased from Quidal Corporation. Anti-MAC rabbit polyclonal anti-
bodies were purchased from Calbiochem. Anti-PrP mousemonoclonal
antibody 6D11 and humanmonoclonal antibody D13 were purchased
from Covance and InPro Biotechnology, respectively. Biotinylated
anti-human IgG was purchased from Jackson ImmunoResearch. All
Alexa-labeled secondary antibodies were purchased from Invitrogen.
Preparation of mouse serum
NMS was prepared from 6 to 8 weeks old RML mice. Blood was
collected from the heart under inhalation anesthesia with isoﬂulane
and coagulated at 4 °C for 6 h. NMS was incubated at 56 °C for
30 min for preparation of H-NMS. Rocky Mountain Laboratories is
an AALAC-accredited facility, and all animal procedures were ap-
proved by the institution's Animal Use and Care Committee.
Treatment of N2a cells with NMS, HS-NMS and FBS
N2a cells persistently infected with Chandler (Race et al., 1998) or
22L scrapie strains (Kocisko et al., 2003) were maintained at 37 °C in a
humidiﬁed atmosphere of 5% CO2 in Opti-MEM supplemented with
10% FBS, 2 mM L-glutamine (Invitrogen) and penicillin/streptomycin
Fig. 5. Summary of distribution of vacuolation, PrPSc, C1q and C3 of Chandler- or 22L-infected mouse at 90 dpi. The colors indicate the severity of vacuolation or relative intensity of
PrPSc, C1q or C3 deposition. Blue, mild; Green, moderate; Orange, strong; Graphics of the sagittal section of mouse brain are from “The Mouse Brain 2nd edition” (Academic Press).
LV: lateral ventricle.
211R. Hasebe et al. / Virology 423 (2012) 205–213(Invitrogen). For the negative controls, the infected cells were treated
with PPS to cure their prion infection. After 5 passages with PPS, PrPSc
was not detected by Western Blotting (data not shown). The cells
were seeded on 24 well plates at approximately 10% (for Chandler)
or 5% conﬂuence (for 22L) and were cultured for 2 days. Then the
cells were cultured with media supplemented with 10% NMS, H-
NMS or FBS for 6, 12, 24 and 48 h. To assess inhibitory effects of
anti-complement antibodies on the cellular exposure of phosphati-
dylserine, NMS was treated with anti-C1q, C3 and/or C9 goat poly-
clonal antibodies at 150 μg/ml of total protein for each antibody. For
controls, NMS was treated with NGS or anti-mouse IgG goat polyclon-
al antibodies at 150 and 450 μg/ml of total protein. Exposure of phos-
phatidylserine on the outer side of the plasma membrane was
detected by Annexin V staining (Invitrogen) according to the manu-
facturer's instructions. Three areas of each well were randomly cho-
sen and Annexin V positive cells were counted. Proportions of
Annexin V positive cells were calculated by dividing by the total num-
ber of cells. Three independent experiments were performed. Cell
deathwas detected by PI uptake. The cellswere incubatedwith PI (Invi-
trogen) at 5 μg/ml for 20 min at 37 °C and observed by ﬂuorescent mi-
croscopy (Nikon).Immunocytochemistry
For MAC detection, the cells were seeded on glass-bottomed Lab-
Tek 8 well chamber slides (Nalge Nunc International). At 6, 12 or 24 h
after treatment with NMS, the cells were ﬁxed with cold methanol for
15 min, dried and blocked with 2% bovine serum albumin (BSA) in
phosphate buffered saline with 0.01% Tween 20. The cells were incu-
bated with anti-MAC antibodies at a 1:100 dilution at 4 °C overnight,
followed by incubation with Alexa568-anti rabbit goat polyclonal an-
tibodies at a 1:800 dilution for 1 h at room temperature. The cells
were counterstained with 4′6-diamidino-2-phenylindole (DAPI) at
1 μg/ml. For double staining of PrP and C1q/C3, the cells were ﬁxed
with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Tri-
ton X-100 for 5 min and blocked with 2% BSA for 15 min at room tem-
perature. For the primary antibodies, the cells were incubated with
anti-PrP (6D11) mouse monoclonal antibody at a 1:1000 dilution
and anti-C1q or C3 goat polyclonal antibodies at a 1:100 dilution.
For the secondary antibodies, Alexa488-labeled anti-goat IgG poly-
clonal antibodies and Alexa 568-labeled anti-mouse IgG polyclonal
antibodies were used at a 1:800 dilution for each. The samples were
observed with an LSM 510 microscope (Carl Zeiss Inc).
Fig. 6. Histopathology of the dorsal part of thalamus at 90 dpi. The slides from Chandler-, 22L- or mock-infected mouse brains were subjected to HE staining (A) and immunohis-
tochemistry for the detection of PrPSc (B), C1q (C) and C3 (D). Green, C1q or C3. Blue, DAPI. Bars show 50 μm.
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C57BL/6mice (8–10 weeks old) were infected intracerebrally with
0.5% Chandler-, 22L-, or normal mouse brain homogenates under in-
halation anesthesia with isoﬂulane. At 90, 133 and 166 dpi, 4 mice
for each strain were euthanized and the brains were harvested. The
samples were ﬁxed with 10% phosphate-buffered formalin, dehy-
drated and embedded in parafﬁn. The parafﬁn blocks were cut at
4 μm and subjected to HE staining and immunohistochemistry for
PrPSc, C1q and C3. PrPSc staining was performed using a Ventana au-
tomated Discovery XT stainer. For antigen retrieval, the slides wereincubated in CC1 buffer (Ventana) containing Tris–borate–EDTA pH
8.0 for 180 min at 95 °C. Then the cells were incubated with anti
mouse PrP human antibody D13 at a dilution of 1:500 at 4 °C for
16 h, followed by a biotinylated anti-human IgG at 1:500 and
avidin-horseradish peroxidase. Then the slides were reacted with dia-
minobenzidine (Ventana) as chromogen and observed with an Olym-
pus BX51 microscope. For C1q and C3 detection, the slides were pre-
treated with 0.03% proteinase K at 37 °C for 30 min, incubated with
anti-C1q or C3 antibodies at 4 °C overnight. Then the slides were in-
cubated with Alexa488-labeled anti goat IgG for secondary antibody
and counterstained with DAPI.
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